Tirofiban in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention / 中国介入心脏病学杂志

ABSTRACT

Objective To explore the safety of tirofiban and short-term outcomes in elder patients (≥70 years old) with non-ST elevation acute coronary syndrome (NSTEACS) undergoing percutaneous coronary intervention (PCI). Methods One hundred and eight patients with NSTEACS were enrolled in the study with 42 patients older than 70 years (Group A) and another 66 patients younger than 70 years (group B). Basic characteristics, immediate success rate of PCI, the incidence of bleeding complications and thrombocytopenia were recorded. Clinical main adverse cardiac events(MACE) including cardiac death, recurrent angina pectoris, myocardial infarction(MI) and heart failure at 30-day were recorded and analyzed. Results Plasma levels of triglycerin and lipoprotein (a) in Group A were higher than that in Group B (2.06?1.38) mmol/L vs (1.53?0.55) mmol/L, P